Corient Private Wealth LLC Invests $320,000 in Xeris Biopharma Holdings, Inc. $XERS

Corient Private Wealth LLC bought a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 68,500 shares of the company’s stock, valued at approximately $320,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 7.2% during the second quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company’s stock worth $17,052,000 after buying an additional 244,862 shares during the last quarter. Qube Research & Technologies Ltd increased its position in Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after acquiring an additional 1,245,188 shares during the period. Goldman Sachs Group Inc. raised its stake in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Millennium Management LLC raised its stake in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Xeris Biopharma by 27.8% in the 2nd quarter. Legal & General Group Plc now owns 1,804,203 shares of the company’s stock valued at $8,426,000 after purchasing an additional 392,589 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Insiders Place Their Bets

In related news, Director John Johnson sold 135,400 shares of Xeris Biopharma stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.22, for a total value of $977,588.00. Following the completion of the transaction, the director directly owned 698,083 shares of the company’s stock, valued at $5,040,159.26. The trade was a 16.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $7.01, for a total transaction of $116,835.67. Following the sale, the insider directly owned 1,320,176 shares in the company, valued at approximately $9,254,433.76. This represents a 1.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 206,976 shares of company stock valued at $1,497,495. Company insiders own 4.56% of the company’s stock.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS opened at $7.31 on Wednesday. Xeris Biopharma Holdings, Inc. has a 52-week low of $3.14 and a 52-week high of $10.08. The business has a fifty day moving average of $7.66 and a two-hundred day moving average of $7.03. The stock has a market cap of $1.21 billion, a PE ratio of -73.09 and a beta of 0.58.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to analysts’ expectations of $74.19 million. Analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

XERS has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Piper Sandler upped their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Barclays assumed coverage on Xeris Biopharma in a report on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective on the stock. Finally, Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.50.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.